Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 26,678,500 | $633,080,805 | +1% | 2.87% |
| 2. | AQR Capital Management Cliff Asness | 2,911,379 | $69,087,023 | +34% | 0.11% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 1,755,890 | $41,667,270 | -5% | 0.09% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 987,094 | $23,423,741 | 0.21% | |
| 5. | GLG Partners Noam Gottesman | 658,859 | $15,634,724 | -14% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 225,000 | Director | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | Director | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | Director | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | Director | 910,730 | 2023-11-27 | Filing | |
| $4.95 | 20,000 | Director | 568,273 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 8,287 | Director | 349,499 | 2024-06-04 | Filing | |
| $21.12 | 27,280 | Director | 5,445 | 2024-05-21 | Filing | |
| $20.96 | 11,686 | Director | 213,907 | 2024-05-21 | Filing | |
| $21.00 | 11,437 | Director | 1,260,578 | 2024-05-20 | Filing | |
| $21.37 | 10,923 | Director | 338,948 | 2024-05-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 36,014,432 | $863,986,223 | 0.02% | |
| 2. | 31,671,090 | $759,789,450 | 0.01% | |
| 3. | 13,032,818 | $312,657,304 | 0.01% | |
| 4. | 7,741,589 | $185,720,735 | 0.01% | |
| 5. | 5,145,318 | $123,455,190 | 0.01% |
News See All
Insiders Are Dumping These 10 Healthcare Stocks
In this article, we will take a detailed look at Insiders Are Dumping These 10 Healthcare Stocks. For a quick overview of such stocks, read our article Insiders Are Dumping These 5 Healthcare Stocks...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
10 Mid-Cap Stocks with Insider Purchases
Investors are yet again in a wait-and-see mode ahead of key jobs and inflation numbers, but the overall sentiment in the market is positive, helped by the Fed Chair Jerome Powell’s latest statement ...
Exelixis, Inc. (NASDAQ:EXEL) Q4 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. My name is Tawanda, and I will be your operator for today.
11 Stocks Insiders and Billionaires Are Crazy About
In this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are...
Exelixis, Inc. (NASDAQ:EXEL) Q3 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Third Quarter 2023 Financial Results Conference Call. My name is Gigi, and I'll be your operator for today.
14 Best Cancer Stocks To Buy Now
The global oncology landscape continues to evolve, with ongoing efforts to discover, develop, and provide innovative treatments aimed at improving outcomes for a growing number of patients.
Exelixis, Inc. (NASDAQ:EXEL) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call. My name is Tawanda and I'll be your operator for today.
Billionaire Hedge Funds
